Araujo da Silva André Ricardo, de Carvalho Bernardo Rodrigues Rosa, Esteves Monica Del Monaco, Teixeira Cristiane Henriques, Souza Cristina Vieira
Materno-Infantil Department, Faculty of Medicine, Fluminense Federal University, Niterói 24033-900, Brazil.
Infection Control Committee, Prontobaby Group, Rio de Janeiro 20540-100, Brazil.
Vaccines (Basel). 2022 Apr 15;10(4):619. doi: 10.3390/vaccines10040619.
Objective: To evaluate COVID-19 vaccination status in admitted children in 2020−2021 and during the OMICRON variant circulation (2022), a period when children older than 12 years of age had received two doses of COVID-19 vaccines. Design: An observational retrospective study. Patients with confirmed COVID-19 were compared in two different periods: 2020−2021 when adolescents aged 12−18 years had not received the complete COVID-19 vaccine, and 2022 when children older than 12 years had received the complete Pfizer-BioNTech vaccine scheme. Setting: Two pediatric hospitals in Rio de Janeiro city. Patients: Children aged < 18 years with confirmed COVID-19. Intervention: None. Main outcome: Vaccination status for COVID-19 on admission. Results: In total, 300 patients were admitted with confirmed COVID-19 (240 in 2020−2021 and 60 in 2022). The distribution of patients according to the age-groups was: 0−2 years (33.3% in 2020−2021 and 53.4% in 2022), 2−5 years (21.7% in 2020−2021 and 10% in 2022), 5−11 years (29.2% in 2020−2021 and 28.3% in 2022), and 12−18 years (15.8% in 2020−2021 and 8.3% in 2022) (p = 0.076). The median length of stay was six days in 2020−2021 and six days in 2022 (p = 0.423). We verified six deaths in the first analysis period and one death in the second one (p = 0.894). Of the 60 children admitted in 2022, 58 (96.7%) did not receive the complete COVID-19 vaccine scheme available. Conclusions: We verified in a “real-world condition” the ability of the Pfizer-BioNTech vaccine to prevent hospitalization in children over 12 years of age.
评估2020 - 2021年以及奥密克戎变异株流行期间（2022年）确诊新冠病毒感染的住院儿童的新冠病毒疫苗接种情况，此期间12岁以上儿童已接种两剂新冠病毒疫苗。设计：一项观察性回顾性研究。将确诊新冠病毒感染的患者在两个不同时期进行比较：2020 - 2021年，12 - 18岁青少年尚未接种完新冠病毒疫苗；2022年，12岁以上儿童已接种完辉瑞 - 生物科技公司的疫苗接种方案。背景：里约热内卢市的两家儿科医院。患者：确诊新冠病毒感染的18岁以下儿童。干预措施：无。主要结局：入院时的新冠病毒疫苗接种状况。结果：共有300例确诊新冠病毒感染的患者入院（2020 - 2021年240例，2022年60例）。按年龄组划分的患者分布情况为：0 - 2岁（2020 - 2021年占33.3%，2022年占53.4%），2 - 5岁（2020 - 2021年占21.7%，2022年占10%），5 - 11岁（2020 - 2021年占29.2%，2022年占28.3%），以及12 - 18岁（2020 - 2021年占15.8%，2022年占8.3%）（p = 0.076）。2020 - 2021年的中位住院时间为6天，2022年为6天（p = 0.423）。我们在第一个分析期核实到6例死亡病例，第二个分析期有1例死亡（p = 0.894）。在2022年入院的60名儿童中，58名（96.7%）未接种完可用的新冠病毒疫苗接种方案。结论：我们在“实际情况”中验证了辉瑞 - 生物科技公司的疫苗对12岁以上儿童预防住院的能力。
